Allergan Inc (AGN) 165.84 $AGN
Novartis' Zykadia Gets FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 5:10PM CDT
Novartis (NVS) received positive news when the U.S. Food and Drug Administration (FDA) approved Zykadia for the treatment of patients suffering from anaplastic lymphoma kinase-positive (ALK+) metastatic NSCLC.
Ironwood Up as Loss Narrows, Linzess Shines - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:45PM CDT
Ironwood Pharmaceuticals, Inc. (IRWD) reported a loss of 38 cents per share in the first quarter of 2014.
Will Mylan (MYL) Miss Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:26PM CDT
Mylan (MYL) is set to report first quarter 2014 results on May 1 before the market opens.
United States Migraine Drug Forecast and Market Analysis to 2023: Epidemiology, Etiology, Symptoms, Diagnosis, Pathology and Treatment Guidelines
M2 - Wed Apr 30, 9:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h6hh5c/pharmapoint) has announced the addition of the "PharmaPoint: Migraine - US Drug Forecast and Market Analysis to 2023" report to their offering. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile. The US migraine market is the largest given its population size and high drug prices. The main growth driver during this period will be Allergan's Botox, in addition to the launch of new combinations of drug and device and new classes of acute therapy. Historically the triptans have dominated the acute migraine segment and although the gold standard, GSK's Imitrex, expired in 2008, it has remained as one of the most popular triptans among physicians. A recent trend in this segment is the development of devices that can deliver drugs in a more effective way, such as Sumavel DosePro, a needle-free injection of sumatriptan. Scope - Overview of Migraine including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in the US from 2012-2023. - Analysis of the impact of key events as well the drivers and restraints affecting the US Migraine market. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 3.1 Etiology and Pathophysiology 3.2 Symptoms - Premonitory Phase - Aura Phase - Headache Phase - Postdrome Phase 4 Disease Management - Treatment Overview - Acute Migraine Treatment - Preventive Migraine Treatment 5 Competitive Assessment - Product Profiles- Major Brands - Triptans - Imitrex (sumatriptan) - Zomig (zolmitriptan) - Amerge (naratriptan) - Maxalt (rizatriptan) - Axert (almotriptan) - Frova (frovatriptan) - Relpax (eletriptan) - Sumavel DosePro (sumatriptan) - Ergot Alkaloids - Beta Blockers - Anti-Epileptics - Antidepressants - Calcium Channel Antagonists - Botox (onabotulinum toxin A) 6 Opportunity and Unmet Need 6.1 Overview - A Lack of Acute Therapies for Patients with or at Risk of Cardiovascular Disorders - Lack of Acute Therapies for Patients Unresponsive to Triptan Medication - Lack of Diagnostic Tools Causes Misdiagnosis - Physician Education - Effective and Well-Tolerated Prophylactic Therapies 6.2 Unmet Needs Gap Analysis - Acute Therapies for Patients with or at Risk of Cardiovascular Disorders and for Patients Unresponsive to Triptan Medication - Effective and Well-Tolerated (Migraine-Specific) Preventive Therapies - Physician Education - Diagnostic Tools 7 Pipeline Assessment - Zecuity - Levadex - RHB-103 - AVP-825 - Lasmiditan - MK-1602 - SUD-001 - RT-001 - NXN-188 8 Market Outlook - Forecast - Key Events - Drivers and Barriers 9 Appendix For more information visit http://www.researchandmarkets.com/research/h6...harmapoint
Allergan Shares Up 31.1% Since SmarTrend's Buy Recommendation (AGN)
Comtex SmarTrend(R) - Wed Apr 30, 9:11AM CDT
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on April 15th, 2014 at $125.97. In approximately 2 weeks, Allergan has returned 31.13% as of today's recent price of $165.18.
Will Allergan Buy Its Way out of a Takeover?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Apr 29, 6:13PM CDT
There has been no shortage of drama relating to Valeant Pharmaceuticals' proposed takeover of Allergan . Valeant's proposed takeover is estimated to generate a potential $2.7 billion in cost savings for the combined company, in part by...
Can Hospira (HSP) Keep the Earnings Streak Alive? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 4:10PM CDT
We expect Hospira (HSP) to beat expectations when it reports first quarter 2014 results on Apr 30 before the opening bell.
Stocks Finish Higher on Solid Earnings
at The Street - Tue Apr 29, 3:14PM CDT
Stocks close higher Tuesday amid a solid spate of earnings, even as economic reports suggest a muted beginning to the year. Easing geopolitical tensions in Ukraine help boost sentiment.
Research and Markets: Global Glaucoma Therapeutics Market 2014-2018: Allergan Inc., Merck & Co. Inc., Novartis AG & Pfizer Dominate the Industry
Business Wire - Tue Apr 29, 2:36PM CDT
Research and Markets (http://www.researchandmarkets.com/research/l62h48/global_glaucoma) has announced the addition of the "Global Glaucoma Therapeutics Market 2014-2018" report to their offering.
AstraZeneca Soars as Pfizer Confirms Buyout Talks - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 1:38PM CDT
AstraZeneca's (AZN) shares soared 12.16% after a statement was released by Pfizer (PFE) confirming that it had discussions with the former regarding a possible merger.
Bristol, Merck, Sanofi Report Soft Q1 Sales
at Investor's Business Daily - Tue Apr 29, 11:15AM CDT
Three big pharmas reported light-to-mixed Q1 earnings Tuesday, but their shares went in different directions in the stock market today as Wall Street seemed to focus on different details of the reports. Bristol-Myers Squibb (BMY) said Q1 earnings...
Stocks Modestly Higher; Earnings Lift MGM
at Investor's Business Daily - Tue Apr 29, 10:56AM CDT
Stocks were off their session highs Tuesday, but still modestly higher after a batch of earnings reports and mixed housing and sentiment data. The Nasdaq rose 0.5% and the S&P 500 climbed 0.4%. Both were up as much as 0.7% and 0.5% intraday....
Global Glaucoma Therapeutics Market 2014-2018: Allergan Inc, Merck & Co. Inc, Novartis AG & Pfizer Dominate the Industry
M2 - Tue Apr 29, 10:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kqdgkx/global_glaucoma) has announced the addition of the "Global Glaucoma Therapeutics Market 2014-2018" report to their offering. There is a high degree of R&D in the early stages of development in the glaucoma therapeutics pipeline. Some of the new pipeline products, in the early stages of development possess novel mechanisms of action such as ROCK inhibitors, or the VEGF inhibitors. The new drugs in the early stage pipeline with novel mechanisms of action are targeting the cause of the disease rather than providing symptomatic relief. These drugs could significantly cater to the existing unmet needs of the market but are not expected to be launched and to have any influence during the forecast period. For instance, Muscarinic (phase I), a small molecule by ACADIA Pharmaceuticals Inc., AR-13324 (phase II), a ROCK inhibitor by Aerie Pharmaceuticals Inc. are novel molecules and are expected to fulfill the existing unmet needs of the Global Glaucoma Therapeutics market. According to the report, the Global Glaucoma Therapeutics market is driven by several factors, of which the increasing prevalence of eye disorders is one of the major drivers. An increase in the prevalence of eye disorders around the world has consequently led to a rise in the incidence of age-related eye diseases. Glaucoma is the most common type of age-related eye disorder. Further, the report states that the increasing number of patent expirations is one of the main challenges. The patent expiries of major approved drugs will slow down the market growth during the forecast period, thereby reducing the overall market value. The Global Glaucoma Therapeutics market can be divided into five segments: - Prostaglandins - Beta Blockers - Alpha Adrenergic Agonists - Carbonic Anhydrase Inhibitors - Fixed Dose Combinations. Key Vendors - Allergan Inc. - Merck & Co. Inc. - Novartis AG - Pfizer Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Pipeline Snapshot - Rate of Incidence and Prevalence - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/kq...l_glaucoma
Bayer Gains on Q1 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 10:00AM CDT
Bayer's (BAYRY) earnings during the first quarter of 2014 came in at $2.67 compared with $2.25 per share in the year-ago period.
Merck Tops Q1 Earnings Expectations, Affirms Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 9:46AM CDT
Merck's (MRK) first quarter results were mixed with the company beating on earnings but missing on revenues.
RadNet (RDNT) Catches Eye: Stock Rises 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 8:46AM CDT
RadNet (RDNT) was a big mover last session, with shares rising over 6% on the day.
Why Shire (SHPG) Stock Is Higher In Pre-Market Trade
at The Street - Tue Apr 29, 7:23AM CDT
Shares of Shire (SHPG) are up 1.81% to $175.45 in pre-market trade after Allergan (AGN) will reportedly approach Shire again about a potential takeover after being rebuffed in recent months.
PharmaPoint: Migraine - Current and Future Players 2014
M2 - Tue Apr 29, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5djb5h/pharmapoint) has announced the addition of the "PharmaPoint: Migraine - Current and Future Players" report to their offering. PharmaPoint: Migraine - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Migraine Market. The report identifies and analyses the key companies shaping and driving the global Migraine market. The report provides insight into the competitive Migraine landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Our team of industry experts. Scope - Investigation of current and future market competition for Migraine - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Migraine sector through market impact analysis, future market scenario and company analysis Key Topics Covered: - Tables & Figures - Introduction - Market Outlook - Current and Future Players - GlaxoSmithKline - AstraZeneca - Merck - Vernalis - Almirall - Pfizer - Zogenix - NuPathe - Allergan - RedHill Biopharma - OptiNose - CoLucid Pharmaceuticals - SUDA - Revance Therapeutics - NeurAxon For more information visit http://www.researchandmarkets.com/research/5d...harmapoint
Global Anti-aging Market 2013-2019 - North America Lead the Way
M2 - Tue Apr 29, 3:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sxj3lx/antiaging_market) has announced the addition of the "Anti-aging Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Anti-aging market is growing as modern technologies have initiated the involvement of novel anti-aging treatments and products. Anti-aging market is segmented into products, services and devices. Anti-aging product market compared to services was observed to be resilient to economic cycles because it was observed that during a financial downturn customers shifted to cost efficient mass marketed products which prevented any major declination in products market. Anti-aging market can also be segmented on the basis of age demographics such as baby boomers, generation X and generation Y. Baby boomers are observed to the major target for anti-aging industry as this generation is aging and have high disposable income. According to a statistical data, 44% of US population is of Baby Boomers and 70% of US's disposable income is owned by Baby boomers. It was also observed that baby boomers and generation X are the most aware and potential customers for anti-aging market. This age group is investing more into anti-aging products market as they have already crossed 50 years and now expect to delay or mask the aging signs whereas generation X is investing more in anti-aging services market to maintain their appearance as they have reached in their forties. Anti-aging market consists of products, services and devices among which by revenue product segment leads the market followed by services and devices. The future growth of products market was observed to depend on the innovation and technological development with increase in the efficacy and safety of anti-aging products. North America is the leading geography for anti-aging market due to high awareness about aging signs, rise in obesity and sedentary lifestyle which are the major drivers of this market. Anti-aging services and products market are observed to be more mature markets than devices but demand for devices for personal use is increasing in this geography. Asia- Pacific market is expected to grow as the acceptance of new product, service or device has been increased over years due to awareness among population of Asia-Pacific and their growing economies have also added up to their disposable income capacities. Key Topics Covered: - Introduction - Executive Summary - Market Overview - Global Anti-aging Market by Demographics, Size and Forecast, 2011 - 2019 (USD Million) - Global Anti-aging Market by Products, Size and Forecast, 2011-2019 (USD Million) - Global Anti-aging Market, by Services, 2011 - 2019 (USD Million) - Global Anti-aging Market by Devices, Size and Forecast, 2011-2019 (USD Million) - Global Anti-aging Market by Geography, Size and Forecast, 2011-2019 (USD Million) - Recommendations - Company Profiles - Allergan, Inc. - Alma Laser - Beiersdorf AG - Coty Inc. - Cynosure - Lumenis - L'Or?al SA - Personal Microderm (PMD) - Photomedex - Solta Medical, Inc. For more information visit http://www.researchandmarkets.com/research/sx...ing_market
Data on Novartis' Onbrez Breezhaler - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 5:10PM CDT
Novartis (NVS) announced positive top-line results from a phase IV study, INSTEAD, on Onbrez Breezhaler.
Novartis' Zykadia Gets FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 5:10PM CDT
Novartis (NVS) received positive news when the U.S. Food and Drug Administration (FDA) approved Zykadia for the treatment of patients suffering from anaplastic lymphoma kinase-positive (ALK+) metastatic NSCLC.
Ironwood Up as Loss Narrows, Linzess Shines - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:45PM CDT
Ironwood Pharmaceuticals, Inc. (IRWD) reported a loss of 38 cents per share in the first quarter of 2014.
Will Mylan (MYL) Miss Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:26PM CDT
Mylan (MYL) is set to report first quarter 2014 results on May 1 before the market opens.
United States Migraine Drug Forecast and Market Analysis to 2023: Epidemiology, Etiology, Symptoms, Diagnosis, Pathology and Treatment Guidelines
M2 - Wed Apr 30, 9:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h6hh5c/pharmapoint) has announced the addition of the "PharmaPoint: Migraine - US Drug Forecast and Market Analysis to 2023" report to their offering. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile. The US migraine market is the largest given its population size and high drug prices. The main growth driver during this period will be Allergan's Botox, in addition to the launch of new combinations of drug and device and new classes of acute therapy. Historically the triptans have dominated the acute migraine segment and although the gold standard, GSK's Imitrex, expired in 2008, it has remained as one of the most popular triptans among physicians. A recent trend in this segment is the development of devices that can deliver drugs in a more effective way, such as Sumavel DosePro, a needle-free injection of sumatriptan. Scope - Overview of Migraine including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in the US from 2012-2023. - Analysis of the impact of key events as well the drivers and restraints affecting the US Migraine market. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 3.1 Etiology and Pathophysiology 3.2 Symptoms - Premonitory Phase - Aura Phase - Headache Phase - Postdrome Phase 4 Disease Management - Treatment Overview - Acute Migraine Treatment - Preventive Migraine Treatment 5 Competitive Assessment - Product Profiles- Major Brands - Triptans - Imitrex (sumatriptan) - Zomig (zolmitriptan) - Amerge (naratriptan) - Maxalt (rizatriptan) - Axert (almotriptan) - Frova (frovatriptan) - Relpax (eletriptan) - Sumavel DosePro (sumatriptan) - Ergot Alkaloids - Beta Blockers - Anti-Epileptics - Antidepressants - Calcium Channel Antagonists - Botox (onabotulinum toxin A) 6 Opportunity and Unmet Need 6.1 Overview - A Lack of Acute Therapies for Patients with or at Risk of Cardiovascular Disorders - Lack of Acute Therapies for Patients Unresponsive to Triptan Medication - Lack of Diagnostic Tools Causes Misdiagnosis - Physician Education - Effective and Well-Tolerated Prophylactic Therapies 6.2 Unmet Needs Gap Analysis - Acute Therapies for Patients with or at Risk of Cardiovascular Disorders and for Patients Unresponsive to Triptan Medication - Effective and Well-Tolerated (Migraine-Specific) Preventive Therapies - Physician Education - Diagnostic Tools 7 Pipeline Assessment - Zecuity - Levadex - RHB-103 - AVP-825 - Lasmiditan - MK-1602 - SUD-001 - RT-001 - NXN-188 8 Market Outlook - Forecast - Key Events - Drivers and Barriers 9 Appendix For more information visit http://www.researchandmarkets.com/research/h6...harmapoint
Allergan Shares Up 31.1% Since SmarTrend's Buy Recommendation (AGN)
Comtex SmarTrend(R) - Wed Apr 30, 9:11AM CDT
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on April 15th, 2014 at $125.97. In approximately 2 weeks, Allergan has returned 31.13% as of today's recent price of $165.18.
Will Allergan Buy Its Way out of a Takeover?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Apr 29, 6:13PM CDT
There has been no shortage of drama relating to Valeant Pharmaceuticals' proposed takeover of Allergan . Valeant's proposed takeover is estimated to generate a potential $2.7 billion in cost savings for the combined company, in part by...
Can Hospira (HSP) Keep the Earnings Streak Alive? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 4:10PM CDT
We expect Hospira (HSP) to beat expectations when it reports first quarter 2014 results on Apr 30 before the opening bell.
Stocks Finish Higher on Solid Earnings
at The Street - Tue Apr 29, 3:14PM CDT
Stocks close higher Tuesday amid a solid spate of earnings, even as economic reports suggest a muted beginning to the year. Easing geopolitical tensions in Ukraine help boost sentiment.
Research and Markets: Global Glaucoma Therapeutics Market 2014-2018: Allergan Inc., Merck & Co. Inc., Novartis AG & Pfizer Dominate the Industry
Business Wire - Tue Apr 29, 2:36PM CDT
Research and Markets (http://www.researchandmarkets.com/research/l62h48/global_glaucoma) has announced the addition of the "Global Glaucoma Therapeutics Market 2014-2018" report to their offering.
AstraZeneca Soars as Pfizer Confirms Buyout Talks - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 1:38PM CDT
AstraZeneca's (AZN) shares soared 12.16% after a statement was released by Pfizer (PFE) confirming that it had discussions with the former regarding a possible merger.
Bristol, Merck, Sanofi Report Soft Q1 Sales
at Investor's Business Daily - Tue Apr 29, 11:15AM CDT
Three big pharmas reported light-to-mixed Q1 earnings Tuesday, but their shares went in different directions in the stock market today as Wall Street seemed to focus on different details of the reports. Bristol-Myers Squibb (BMY) said Q1 earnings...
Stocks Modestly Higher; Earnings Lift MGM
at Investor's Business Daily - Tue Apr 29, 10:56AM CDT
Stocks were off their session highs Tuesday, but still modestly higher after a batch of earnings reports and mixed housing and sentiment data. The Nasdaq rose 0.5% and the S&P 500 climbed 0.4%. Both were up as much as 0.7% and 0.5% intraday....
Global Glaucoma Therapeutics Market 2014-2018: Allergan Inc, Merck & Co. Inc, Novartis AG & Pfizer Dominate the Industry
M2 - Tue Apr 29, 10:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kqdgkx/global_glaucoma) has announced the addition of the "Global Glaucoma Therapeutics Market 2014-2018" report to their offering. There is a high degree of R&D in the early stages of development in the glaucoma therapeutics pipeline. Some of the new pipeline products, in the early stages of development possess novel mechanisms of action such as ROCK inhibitors, or the VEGF inhibitors. The new drugs in the early stage pipeline with novel mechanisms of action are targeting the cause of the disease rather than providing symptomatic relief. These drugs could significantly cater to the existing unmet needs of the market but are not expected to be launched and to have any influence during the forecast period. For instance, Muscarinic (phase I), a small molecule by ACADIA Pharmaceuticals Inc., AR-13324 (phase II), a ROCK inhibitor by Aerie Pharmaceuticals Inc. are novel molecules and are expected to fulfill the existing unmet needs of the Global Glaucoma Therapeutics market. According to the report, the Global Glaucoma Therapeutics market is driven by several factors, of which the increasing prevalence of eye disorders is one of the major drivers. An increase in the prevalence of eye disorders around the world has consequently led to a rise in the incidence of age-related eye diseases. Glaucoma is the most common type of age-related eye disorder. Further, the report states that the increasing number of patent expirations is one of the main challenges. The patent expiries of major approved drugs will slow down the market growth during the forecast period, thereby reducing the overall market value. The Global Glaucoma Therapeutics market can be divided into five segments: - Prostaglandins - Beta Blockers - Alpha Adrenergic Agonists - Carbonic Anhydrase Inhibitors - Fixed Dose Combinations. Key Vendors - Allergan Inc. - Merck & Co. Inc. - Novartis AG - Pfizer Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Pipeline Snapshot - Rate of Incidence and Prevalence - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/kq...l_glaucoma
Bayer Gains on Q1 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 10:00AM CDT
Bayer's (BAYRY) earnings during the first quarter of 2014 came in at $2.67 compared with $2.25 per share in the year-ago period.
Merck Tops Q1 Earnings Expectations, Affirms Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 9:46AM CDT
Merck's (MRK) first quarter results were mixed with the company beating on earnings but missing on revenues.
RadNet (RDNT) Catches Eye: Stock Rises 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 8:46AM CDT
RadNet (RDNT) was a big mover last session, with shares rising over 6% on the day.
Why Shire (SHPG) Stock Is Higher In Pre-Market Trade
at The Street - Tue Apr 29, 7:23AM CDT
Shares of Shire (SHPG) are up 1.81% to $175.45 in pre-market trade after Allergan (AGN) will reportedly approach Shire again about a potential takeover after being rebuffed in recent months.
PharmaPoint: Migraine - Current and Future Players 2014
M2 - Tue Apr 29, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5djb5h/pharmapoint) has announced the addition of the "PharmaPoint: Migraine - Current and Future Players" report to their offering. PharmaPoint: Migraine - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Migraine Market. The report identifies and analyses the key companies shaping and driving the global Migraine market. The report provides insight into the competitive Migraine landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Our team of industry experts. Scope - Investigation of current and future market competition for Migraine - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Migraine sector through market impact analysis, future market scenario and company analysis Key Topics Covered: - Tables & Figures - Introduction - Market Outlook - Current and Future Players - GlaxoSmithKline - AstraZeneca - Merck - Vernalis - Almirall - Pfizer - Zogenix - NuPathe - Allergan - RedHill Biopharma - OptiNose - CoLucid Pharmaceuticals - SUDA - Revance Therapeutics - NeurAxon For more information visit http://www.researchandmarkets.com/research/5d...harmapoint
Global Anti-aging Market 2013-2019 - North America Lead the Way
M2 - Tue Apr 29, 3:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sxj3lx/antiaging_market) has announced the addition of the "Anti-aging Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Anti-aging market is growing as modern technologies have initiated the involvement of novel anti-aging treatments and products. Anti-aging market is segmented into products, services and devices. Anti-aging product market compared to services was observed to be resilient to economic cycles because it was observed that during a financial downturn customers shifted to cost efficient mass marketed products which prevented any major declination in products market. Anti-aging market can also be segmented on the basis of age demographics such as baby boomers, generation X and generation Y. Baby boomers are observed to the major target for anti-aging industry as this generation is aging and have high disposable income. According to a statistical data, 44% of US population is of Baby Boomers and 70% of US's disposable income is owned by Baby boomers. It was also observed that baby boomers and generation X are the most aware and potential customers for anti-aging market. This age group is investing more into anti-aging products market as they have already crossed 50 years and now expect to delay or mask the aging signs whereas generation X is investing more in anti-aging services market to maintain their appearance as they have reached in their forties. Anti-aging market consists of products, services and devices among which by revenue product segment leads the market followed by services and devices. The future growth of products market was observed to depend on the innovation and technological development with increase in the efficacy and safety of anti-aging products. North America is the leading geography for anti-aging market due to high awareness about aging signs, rise in obesity and sedentary lifestyle which are the major drivers of this market. Anti-aging services and products market are observed to be more mature markets than devices but demand for devices for personal use is increasing in this geography. Asia- Pacific market is expected to grow as the acceptance of new product, service or device has been increased over years due to awareness among population of Asia-Pacific and their growing economies have also added up to their disposable income capacities. Key Topics Covered: - Introduction - Executive Summary - Market Overview - Global Anti-aging Market by Demographics, Size and Forecast, 2011 - 2019 (USD Million) - Global Anti-aging Market by Products, Size and Forecast, 2011-2019 (USD Million) - Global Anti-aging Market, by Services, 2011 - 2019 (USD Million) - Global Anti-aging Market by Devices, Size and Forecast, 2011-2019 (USD Million) - Global Anti-aging Market by Geography, Size and Forecast, 2011-2019 (USD Million) - Recommendations - Company Profiles - Allergan, Inc. - Alma Laser - Beiersdorf AG - Coty Inc. - Cynosure - Lumenis - L'Or?al SA - Personal Microderm (PMD) - Photomedex - Solta Medical, Inc. For more information visit http://www.researchandmarkets.com/research/sx...ing_market
Data on Novartis' Onbrez Breezhaler - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 5:10PM CDT
Novartis (NVS) announced positive top-line results from a phase IV study, INSTEAD, on Onbrez Breezhaler.
